Here's what we'll cover
Here's what we'll cover
If you're a state government employee using a GLP-1 medication like Wegovy or Ozempic for weight loss, your coverage situation may be about to shift. States across the country are re-evaluating what their employee health plans will cover, and GLP-1 drugs are at the center of those conversations.
The reason is straightforward: these medications work, but they are expensive. And when a state health plan covers thousands of employees, even modest uptake of a drug that costs $900 to $1,300 per month adds up fast.
Why States Are Revisiting GLP-1 Coverage Now
GLP-1 receptor agonists (a class of medications that mimic a gut hormone to reduce appetite and regulate blood sugar) have surged in demand since semaglutide and tirzepatide gained FDA approval for chronic weight management. The clinical results are compelling, with trials showing 15% to 22% body weight reduction in eligible patients.
But the cost burden on employer health plans has become significant. A 2024 analysis by the Employee Benefit Research Institute found that GLP-1 drug spending among insured workers increased by more than 400% between 2021 and 2023. For state governments managing tight budgets and large employee pools, this has triggered policy reviews.
Some states are pulling back coverage. Others are actually expanding it. The outcome for you depends entirely on which state employs you and how that state's benefits administrators have responded to the cost pressure.
What "Changing the Rules" Actually Means for Patients
When a state revises its GLP-1 coverage policies, the changes typically fall into a few categories. Understanding which type applies to your plan tells you what to expect.
Prior Authorization Requirements
Many plans that previously covered GLP-1s with minimal friction are now adding prior authorization (PA) steps. This means your prescribing physician must submit documentation showing that you meet specific criteria before the plan will pay. Common criteria include a BMI of 30 or above, or 27 or above with a weight-related condition like type 2 diabetes, high blood pressure, or sleep apnea.
Step Therapy Protocols
Step therapy requires patients to try and fail at least one cheaper treatment before a plan will approve a more expensive one. For GLP-1 coverage, this might mean documenting participation in a structured weight loss program or use of an older, lower-cost medication first.
Coverage Caps or Cost Sharing Changes
Some plans are keeping GLP-1s on formulary (the list of covered drugs) but shifting more of the cost to employees. This can mean higher copays, a higher deductible tier, or a coinsurance structure where you pay a percentage of the drug's list price rather than a flat fee.
Removing Coverage Entirely
A smaller number of states have chosen to exclude GLP-1 drugs for weight loss entirely while continuing to cover them for type 2 diabetes management. This distinction matters: the same drug (semaglutide) is marketed as Ozempic for diabetes and Wegovy for weight loss, and your diagnosis code on the prescription can determine whether it's covered at all.
How to Find Out If Your State Plan Is Changing
The most reliable source is your state employee benefits office, not secondhand accounts from coworkers. Here are specific steps to take right now.
Step 1: Request the current formulary. Ask for the updated drug formulary for your plan year. Look for your medication by both brand name and generic name (semaglutide, tirzepatide, liraglutide).
Step 2: Ask about prior authorization criteria. Even if your drug is listed, PA requirements may have changed. Ask HR or the plan administrator what documentation your doctor will need to submit.
Step 3: Check the tier placement. Formularies organize drugs into tiers that correspond to cost sharing levels. If your GLP-1 moved from Tier 2 to Tier 4, your monthly copay could jump significantly.
Step 4: Look at the open enrollment dates. If your plan is changing mid-year, you may have a special enrollment period that lets you switch to a plan with better GLP-1 coverage.
What This Costs You If Coverage Is Reduced
Without insurance coverage or with reduced coverage, the out-of-pocket reality for GLP-1 medications is steep.
Manufacturer savings programs are not available to patients using government-funded insurance, including Medicare and Medicaid. But state employee health plans are typically commercial plans, which means you may still qualify. Check the current options on our GLP-1 Coupons page for updated eligibility details.
Your Options If State Coverage Gets Cut
Losing or reducing coverage does not mean losing access. It means the pathway to access changes, and in some cases becomes more work and more expensive. Here are your realistic alternatives.
Manufacturer Patient Assistance Programs
Both Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) offer patient assistance programs for people who meet income criteria. These programs can provide medication at low or no cost if you qualify.
Telehealth Providers With Cash-Pay Options
Several telehealth platforms prescribe GLP-1 medications and work with compounding pharmacies that offer semaglutide or tirzepatide at significantly lower prices than brand-name equivalents. The FDA lifted its shortage status for semaglutide in early 2025, which created some regulatory complexity around compounded versions. Tirzepatide compounding remains more widely available at this time. Visiting our Best Providers page gives you a current side-by-side comparison of platforms, pricing, and what each one requires for a prescription.
Appealing a Prior Authorization Denial
If your plan denies coverage through a PA process, you have the right to appeal. Ask your doctor to write a letter of medical necessity that documents your weight-related health conditions, previous treatments attempted, and clinical rationale for the prescribed GLP-1. Many denials are overturned at the first appeal level.
Switching Medications
If your plan covers one GLP-1 but not another, talk to your doctor about whether a covered alternative would be appropriate for your situation. Not every medication works identically, but several options exist across different tiers of coverage.
What Employers and States Are Weighing
It helps to understand the other side of this equation, not to excuse restrictive coverage, but to anticipate what policy changes may look like and how to respond.
State health plan administrators are balancing real budget pressures. A state employing 50,000 workers, where even 5% begin using GLP-1 drugs at $1,200 per month, faces roughly $36 million per year in new drug spending. That figure gets attention from budget offices.
At the same time, research is accumulating that GLP-1 use reduces downstream medical costs, including hospitalizations related to cardiovascular events, joint replacements tied to obesity, and diabetes complications. A 2023 SELECT trial published in the New England Journal of Medicine found that semaglutide reduced major cardiovascular events by 20% in people with obesity but without diabetes. That kind of long-term cost offset is increasingly part of the conversation in benefits management circles, though it does not always win the short-term budget argument.
Some states are threading this needle by covering GLP-1s only for employees with documented cardiovascular risk factors or obesity-related comorbidities, rather than for weight loss alone. If you're in that situation, having thorough documentation of any related health conditions from your physician is important.
Questions to Ask Your Doctor Before Your Coverage Changes
If you're currently on a GLP-1 and your coverage is shifting, the time to have a conversation with your prescriber is now, not after a denial letter arrives.
Here are specific questions worth raising:
- Can you document all of my weight-related health conditions in my chart right now, including high blood pressure, sleep apnea, prediabetes, or any cardiovascular risk factors, so my record is ready if prior authorization is required?
- If my plan requires me to try a cheaper medication first under step therapy rules, what would that look like clinically and how long would I need to document that attempt before qualifying for GLP-1 coverage?
- If my coverage is denied or reduced, can you write a letter of medical necessity on my behalf, and what clinical details would make that letter most persuasive for an appeal?
- Is there a covered GLP-1 alternative on my plan's formulary that you would consider appropriate for my situation if my current medication loses coverage?
- If I need to transition to a compounded version or a telehealth-based prescription while coverage is sorted out, what should I look for to make sure I am getting a safe and legitimate product?
- What is your recommended plan if there is a gap in my medication access, and how do you want to manage any weight regain or appetite rebound during an interruption?
- Are there any additional lab results or clinical measurements I should have on file now that would strengthen a prior authorization submission or appeal?
Being proactive with your provider saves time and reduces the risk of an interruption in treatment. Stopping a GLP-1 medication abruptly often results in weight regain, so continuity matters.
No waiting list. No insurance needed.
Frequently Asked Questions
Can a state employee health plan stop covering GLP-1 drugs for weight loss?
Yes. State employee health plans are not required by federal law to cover GLP-1 medications for weight loss. Each plan sets its own formulary and coverage criteria, and those can change each plan year. If your plan removes coverage, you still have options including manufacturer assistance programs, telehealth providers, and appeals processes.
What is the difference between Ozempic and Wegovy for insurance coverage purposes?
Ozempic (semaglutide) is FDA-approved for type 2 diabetes management, while Wegovy (semaglutide) is FDA-approved specifically for chronic weight management. Even though both contain the same active ingredient, insurers treat them differently. Some plans cover Ozempic for diabetes but exclude Wegovy for weight loss, so your diagnosis and the specific medication prescribed both affect coverage.
What is prior authorization for GLP-1 medications and how do I get it approved?
Prior authorization (PA) is a process where your insurance plan requires your doctor to submit documentation proving you meet specific criteria before covering the drug. For GLP-1s, this typically includes your BMI, related health conditions, and sometimes evidence that other treatments were attempted first. Your doctor's office handles the submission, but you should ask them to start the process early and be prepared to appeal if it's initially denied.
Do GLP-1 manufacturer coupons work with state employee health insurance?
In many cases, yes. Manufacturer savings cards from Novo Nordisk and Eli Lilly generally apply to commercial insurance plans, which includes most state employee health benefit plans. However, they cannot be used with Medicare, Medicaid, or other government-funded programs. Check the specific program terms for your medication and plan type.
What happens if I have to stop my GLP-1 medication because of a coverage change?
Stopping a GLP-1 medication often leads to weight regain, as studies show that much of the weight loss is maintained only while the medication is active. If you face a coverage gap, talk to your doctor about options such as lower-dose maintenance, compounded alternatives, or telehealth platforms that offer more affordable access while you resolve the coverage issue.
Can I appeal if my state health plan denies GLP-1 coverage?
Yes. You have the right to appeal a coverage denial through your plan's internal appeals process. Your doctor can write a letter of medical necessity supporting your case. External appeals to an independent reviewer are also available if the internal appeal is denied. Denials are overturned at a meaningful rate, especially when strong medical documentation is provided.